Breast cancer patients showed significantly reduced prolactin levels and less tumor cells in the S-phase of the cell cycle upon treatment with 1.25–2.5 mg bromocriptine for 5 days (Fentiman et al., 1988). Here, PRL is linked to breast carcinoma.